Peter Larson

Mr. Peter Larson

University of Minnesota - Twin Cities
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SBShubhmita Bhatnagar
Shubhmita Bhatnagar
VRVishnu Revuri
Vishnu Revuri
MSManan Shah
Manan Shah
PLPeter Larson
Peter Larson
ZSZekun Shao
Zekun Shao
Jayanth PanyamJayanth Panyam
Jayanth Panyam
Immunostimulatory adjuvants that potently activate antigen-presenting cells and (in turn) prime cytotoxic T cells are a key component of anticancer vaccines. In this study, we investigated a multi-adjuvant approach combining a TLR 7/8 agonist (522) and a STING agonist (DMXAA) to promote enhanced antigen cross-presentation, stimulate specific antitumor T-cell responses, and provide improved anticancer efficacy. In vitro experiments using bone marrow-derived dendritic cells (BMDCs) confirmed enhanced activation with the 522-DMXAA combination based on both co-stimulatory molecule expression and pro-inflammatory cytokine secretion. The immunization of mice with vaccines comprising both 522 and DMXAA resulted in greater antitumor efficacy in B16F10 melanoma and MB49 bladder tumor models relative to mono-agonist vaccines. Flow cytometry-based analysis of immune cells from immunized mice revealed the significant activation of antigen-presenting cells, increased numbers of activated and Ag-specific CD8+ T cells in the spleen and lymph nodes, modest NK cell activation, and an overall reduction in CD206+ macrophages. These results were supported by an increase in the levels of IFN-γ and a reduction in IL-10 levels in the sera. Taken together, these findings demonstrate the potential of the TLR7/8 and STING agonist combination as vaccine adjuvants to activate both innate and adaptive immune responses.

9 December 2021 in Molbank
Verified
Journal Article
Open access
PDF file
PLPeter Larson
Peter Larson
DFDavid Ferguson
David Ferguson
4-Amino-imidazo-, oxazolo-, and thiazoloquinolines are key structural scaffolds in the design of nucleoside base analogs for use as therapeutic agents. Current strategies for arriving at diverse substitutions at the C6–C9 positions of the thiazolo- and oxazoloquinolines, however, are limited due to difficulties in arriving at the thiazoloquinoline-5N-oxide intermediate using electron deficient aromatic systems. Here, we demonstrate a synthetic route to obtain substituted thiazoloquinolines with electron-withdrawing groups at the C7 position. The target compound, 4-amino-2-butyl-7-methoxycarbonylthiazolo[4,5-c]quinoline, is obtained in eight steps using a 7-bromo surrogate as a precursor to the successful generation of the N-oxide intermediate, and final transformation via Pd-mediated C7-acylation.

3 November 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
JSJohn Schultz
John Schultz
PLPeter Larson
Peter Larson
CSCara Skon-Hegg
Cara Skon-Hegg
SBShubhmita Bhatnagar
Shubhmita Bhatnagar
TKTamara Kucaba
Tamara Kucaba
DFDavid Ferguson
David Ferguson
A series of highly substituted imidazoquinolines were synthesized and evaluated for Toll-like receptor (TLR) 7 and 8 activity and potency in stimulating pro-inflammatory cytokine production. The approach applies structure activity relationship data to evaluate the potentiating effects of ring substitutions to the C7-position. Our results show a clear correlation between the inclusion of a C7 methyl acetate group and TLR7 and 8 activity of substituted imidazoquinoline analogs. The most active compounds identified also contain C2 butyl and N1 aminobenzyl substitutions with several analogs displaying single digit nanomolar TLR7 agonist activity. The immunostimulatory effects of the compounds were further evaluated in vitro using human peripheral blood mononuclear cells (PBMCs) and mouse bone marrow-derived dendritic cells (BMDCs). The most potent compounds induce significant production of TNF-α, IL-1β, and IFN-γ by PBMC and expression of MHC II, CD40, and CD80 on BMDCs. A structural model of the TLR7-agonist complex is presented that shows the C7 acetate forms stabilizing H-bonding contacts with several charged amino acid sidechains near the surface of the receptor. The collective results provide strong evidence that correlates the enhanced potency of the C7 acetate analogs to recognition elements at this new site, providing insight to the design of TLR7 and TLR8 ligands.